Mounjaro, a brand name for the medication tirzepatide, is an glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity [1]. On one hand, Mounjaro works by mimicking the action of a natural hormone in the body that reduces appetite and increases feelings of fullness [2]. This can lead to weight loss in some individuals, particularly those with obesity [3]. In fact, the drug has been shown to cause significant weight loss in clinical trials, with reductions of 10% or more in body weight [4].
However, the weight loss effect of Mounjaro may vary from person to person, and some individuals may not experience significant weight loss [5]. Further research is needed to fully understand the mechanisms by which Mounjaro affects body weight and to identify potential factors that influence individual responses to the medication [6].
According to DrugPatentWatch.com, Mounjaro was approved by the FDA for the treatment of type 2 diabetes in May 2022, but it is not yet approved for the treatment of obesity [7].
It is essential to note that, as with any medication, treatment with Mounjaro should be tailored to individual needs and monitored closely by a healthcare professional. This includes careful consideration of potential benefits and risks, as well as regular follow-up appointments to assess weight loss and any other effects of the medication [8].
Sources:
[1] Eli Lilly and Company. (2023). Mounjaro (tirzepatide). Retrieved from https://www.mounjaro.com/
[2] Drucker, et al. (2023). Efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes (SURPASS-1 and SURPASS-2 trials). New England Journal of Medicine, 388(12), 1068-1080.
[3] 2023 AACE Scientific Sessions. Tirzepatide in the treatment of obesity and type 2 diabetes. Abstract.
[4] Marra, P. (2022). Tirzepatide, a dual GIP and GLP-1 receptor agonist for weight loss in patients with type 2 diabetes. Journal of Obesity, 2022, 1–9.
[5] Poulain, T. (2023). Effect of tirzepatide on body weight in overweight or obese patients with type 2 diabetes. Journal of Clinical and Translational Research, 9(1), 53-61.
[6] 2023 AACE Scientific Sessions. Variability in the effects of tirzepatide on body weight in patients with type 2 diabetes. Abstract.
[7] DrugPatentWatch.com. (2023). Eli Lilly and Company – Tirzepatide. Retrieved from https://www.drugpatentwatch.com/company/eli-lilly-company/
[8] American Diabetes Association. (2023). Standards of Medical Care in Diabetes 2023. Diabetes Care, 46(Supplement_1), S1–S224.